1例肝癌合并慢性乙肝免疫治疗的病例报告及文献分析  

Immunotherapy for hepatocellular carcinoma complicated with chronic hepatitis B:a case report and literature review

作　　者：唐丽英 刘丽萍[1] 宁洁[2] 江洁美[3] Tang Liying;Liu Liping;Ning Jie;Jiang Jiemei(Department of Pharmacy,Gengjiu Clinical College of Anhui Medical University,Hefei 230051,China;Department of Oncology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]安徽医科大学庚玖临床学院药学部,安徽合肥230051 [2]安徽医科大学第一附属医院肿瘤内科,安徽合肥230022 [3]安徽医科大学第一附属医院药剂科,安徽合肥230022

出　　处：《实用药物与临床》2025年第3期197-200,共4页Practical Pharmacy and Clinical Remedies

基　　金：安徽省卫生健康委科研项目(AHWJ2023BAa10001)。

摘　　要：目的探讨肝癌合并乙肝伴有高HBV DNA病毒载量患者接受免疫和靶向治疗的安全性。方法针对1例肝癌合并乙肝伴有高HBV DNA病毒载量接受抗病毒和免疫治疗的病例,查阅文献,分析其治疗方案及药学监护。结果患者抗肿瘤治疗前启动抗乙肝病毒治疗,同时接受免疫和抗病毒治疗,治疗期间监护患者肝功能,未出现乙肝病毒再激活。结论肝癌合并乙肝的患者,如乙肝表面抗原和/或HBV DNA阳性,在接受免疫治疗的同时应合并使用抗病毒药物。Objective To investigate the safety of immune and targeted therapy for patients with hepatocellular carcinoma complicated with hepatitis B and high HBV DNA viral load.Methods A case of hepatocellular carcinoma complicated with hepatitis B and high HBV DNA viral load receiving antiviral and immunotherapy was analyzed,and the treatment plan and pharmaceutical care were analyzed.Results The patient began anti-hepatitis B antiviral therapy before anti-tumor therapy,and received immune and antiviral therapy at the same time.The patient's liver function was monitored during treatment,and hepatitis B virus reactivation did not occur.Conclusion If the patients with hepatocellular carcinoma and hepatitis B are positive for hepatitis B surface antigen and/or HBV DNA,they should use antiviral drugs combined with immunotherapy.

关 键 词：肝癌 乙肝 HBV再激活 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]